Topotecan

drugbox
IUPAC_name = ("S")-10- [(dimethylamino)methyl] -4-ethyl-4,9-
dihydroxy-1"H"-pyrano [3',4':6,7] indolizino [1,2-b]
quinoline-3,14(4"H",12"H")-dione monohydrochloride

---

CAS_number = 123948-87-8
CAS_supplemental = 119413-54-6 (hydrochloride)
ATC_prefix = L01
ATC_suffix = XX17
PubChem = 6419854
DrugBank = APRD00687
C = 23 |H = 23 |N = 3 |O = 5 •HCl
molecular_weight = 457.9 g/mol
bioavailability = NA
protein_bound = 35%
metabolism = Hepatic
elimination_half-life = 2-3 hours
excretion = Renal
pregnancy_category = D (Au, U.S.)
legal_status = ℞-only (U.S.), POM (UK)
routes_of_administration = Intravenous infusion, oral

Topotecan hydrochloride (trade name Hycamtin) is a chemotherapy agent that is a topoisomerase 1 inhibitor. It is used to treat ovarian cancer and lung cancer, as well as other cancer types.

After GlaxoSmithKline received final FDA approval for Hycamtin Capsules on October 15, 2007, Topotecan is the first topoisomerase inhibitor for oral use.

Administration

IV, oral.

ide effects

*Diarrhea
*Low blood counts
*Susceptibility to infection

External links

* [http://www.cancer.gov/Templates/drugdictionary.aspx?CdrID=41185 NCI Drug Dictionary Definition of Topotecan]
* [http://www.cancer.gov/cancertopics/druginfo/topotecanhydrochloride NCI Drug Information for Patients]